Investigators found important differences that may help clinicians better understand how to manage toxicities associated with the therapy. The toxicity profile of chimeric antigen receptor (CAR) T ...
Investigators said longer-term outcomes from chimeric antigen receptor (CAR) T-cell therapies are still a significant question in patients who have non-Hodgkin lymphoma (NHL) or acute lymphoblastic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results